Strongyloidiasis and Diffuse Alveolar Hemorrhage in a Patient with Systemic Lupus Erythematosus
Author(s) -
Fernando GonzalezIbarra,
Parag Anilkumar Chevli,
Lindsey Schachter,
Maninder Kaur,
Sahar Eivaz-Mohammadi,
Basheer Tashtoush,
Jioty Matta,
Amer Syed,
Valentin Marian
Publication year - 2014
Publication title -
case reports in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.2
H-Index - 20
eISSN - 1687-9627
pISSN - 1687-9635
DOI - 10.1155/2014/278390
Subject(s) - medicine , strongyloides stercoralis , diffuse alveolar hemorrhage , lupus nephritis , respiratory distress , bronchoalveolar lavage , cyclophosphamide , respiratory failure , systemic lupus erythematosus , pulmonary hemorrhage , surgery , dermatology , lung , immunology , chemotherapy , disease , helminths
The presence of Strongyloides stercoralis infection in patients with systemic lupus erythematosus (SLE) has been described previously. Strongyloides stercoralis hyperinfection syndrome (SHS) that usually develops in patients under immunosuppressive therapy may affect a variety of organs, but the presentation with diffuse alveolar hemorrhage (DAH) is rare with only a few cases described in the literature. We present the case of a 36-year-old Hispanic female with a past medical history relevant for SLE and a recent diagnosis of lupus nephritis and hypertension. The patient who developed sudden and progressive abdominal pain and respiratory distress, with the presence of bilateral crackles and severe hypoxemia, is currently under treatment with steroids and cyclophosphamide for worsening of lupus nephritis. The patient underwent endotracheal intubation and mechanical ventilation, and computed tomography showed the presence of bilateral pulmonary infiltrates suggestive of DAH. Bronchoalveolar lavage was done and showed the presence of filariform larvae, morphologically consistent with Strongyloides stercoralis . Treatment with ivermectin was started and patient responded to treatment with improvement of clinical status. In conclusion, the development of SHS in patients with lupus, especially when receiving immunosuppressive therapy, is a severe and potentially fatal complication. Early detection and treatment may decrease mortality.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom